Does Trevi Therapeutics (TRVI) Have the Potential to Rally 102.07% as Wall Street Analysts Expect?

Shares of Trevi Therapeutics, Inc. (TRVI) have gained 6.5% over the past four weeks to close the last trading session at $10.64, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $21.5 indicates a potential upside of 102.1%.The mean estimate comprises 12 short-term price targets with a standard deviation of $3.26. While the lowest estimate of $16.00 indicates a 50.4% increase from ...